Cargando…

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We analysed consecutive patients included i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694416/ https://www.ncbi.nlm.nih.gov/pubmed/19401696 http://dx.doi.org/10.1038/sj.bjc.6605030

Ejemplares similares

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Arkenau, H-T, et al.
Publicado: (2008)

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience
por: Olmos, D, et al.
Publicado: (2008)

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey
por: Brunetto, Andre, et al.
Publicado: (2011)

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
por: Molife, L R, et al.
Publicado: (2010)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
por: Moreno Garcia, V, et al.
Publicado: (2012)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
por: Basu, B., et al.
Publicado: (2012)

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
por: Ang, Joo Ern, et al.
Publicado: (2012)

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
por: Ameratunga, Malaka, et al.
Publicado: (2020)

You BETer be aware – learnings from a negative Phase 1 study
por: Postel-Vinay, Sophie, et al.
Publicado: (2019)

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer
por: Ang, J E, et al.
Publicado: (2009)

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
por: Geuna, E, et al.
Publicado: (2015)

Thyrotoxicosis and radioiodine therapy: Does the dose matter?
por: Collier, Andrew
Publicado: (2012)

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
por: Bono, Petri, et al.
Publicado: (2020)

High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter?
por: Sukumaran, Sukesh, et al.
Publicado: (2012)

Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?
por: Postel-Vinay, Sophie, et al.
Publicado: (2020)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015)

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
por: Jones, Robert, et al.
Publicado: (2023)

Tranexamic acid for haemostasis and beyond: does dose matter?
por: Lam, Tammy, et al.
Publicado: (2023)

La communication sur le SRAS : un outil essentiel de santé publique
por: Postel-Vinay, N., et al.
Publicado: (2004)

Does the phase of the menstrual cycle really matter to anaesthesia?
por: Kurdi, Madhuri S, et al.
Publicado: (2018)

Does science matter?
por: Broad, W J, et al.
Publicado: (2003)

The Neural Correlates of Grasping in Left-Handers: When Handedness Does Not Matter
por: Begliomini, Chiara, et al.
Publicado: (2018)

Infliximab in the treatment of refractory uveitis. Does dose really matter?
por: Sukumaran, MD Sukesh, et al.
Publicado: (2011)

Type and dose of gonadotropins in poor ovarian responders: does it matter?
por: Boudry, Liese, et al.
Publicado: (2021)

Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter?
por: Raemy, Samuel, et al.
Publicado: (2023)

Alcohol-Based Hand Sanitizers: Does Gelling Agent Really Matter?
por: d’Angelo, Ivana, et al.
Publicado: (2022)

Prophylactic Cefazolin Dosing and Surgical Site Infections: Does the Dose Matter in Obese Patients?
por: Hussain, Zahid, et al.
Publicado: (2018)

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
por: Ploquin, A, et al.
Publicado: (2012)

Foreign Matter in Alimentary Canal
por: Black, Judson
Publicado: (1895)

Does early orchidopexy reduce risk of testicular cancer?
por: Banerji, John S., et al.
Publicado: (2008)

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
por: Ingles Garces, Alvaro H., et al.
Publicado: (2018)

Choosing the polarity of the phase-encoding direction in diffusion MRI: Does it matter for group analysis?
por: Kennis, M., et al.
Publicado: (2016)

Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania
por: Mitchell, K.R., et al.
Publicado: (2021)

Split dosing of artemisinins does not improve antimalarial therapeutic efficacy
por: White, N. J., et al.
Publicado: (2017)

Probiotic viability – does it matter?
por: Lahtinen, Sampo J.
Publicado: (2012)

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
por: Benson, C, et al.
Publicado: (2007)

Healthcare utilization and expenditures for chronic and acute conditions in Georgia: Does benefit package design matter?
por: Gotsadze, George, et al.
Publicado: (2015)

Does Size Matter? An Analysis of the Effect of Lumbar Disc Herniation Size on the Success of Nonoperative Treatment
por: Gupta, Anmol, et al.
Publicado: (2019)

Senior Adults: Does Body Image Matter?
por: Larsen, Keri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96detb9fqvk6kqcblg2mhb9qi8